DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for acute ischemic stroke and cardio-renal disease. Its lead candidate, DM199, aims to mimic the behavior of naturally occurring human tissue kallikrein-1 (KLK1) proteins to improve collateral circulation in stroke-affected tissue and overall kidney function.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

COM:DIAMEDICA

DiaMedica Therapeutics Inc.

Last Close

4.02

21/11 21:00

Market Cap

113.89M

Beta: -

Volume Today

1.08M

Avg: -

market

industry

website

crunchbase

ipo date

peer of

Metrics